Leuprolide Acetate for Depot Suspension: Lupron

CSR Synopses following approval of a new medicine or a new indication for an approved medicine in the US or EU. We are making CSR synopses available to supplement the public information available to patients and healthcare providers about the results of our clinical trials and the evidence used to approve a new medicine or a new indication.

{m} Entries

Phase
Study Indication or Disease
Study Name
L-PC07-169 AbbVie_IU_icons_outlined_v3 Other Phase 3 A Phase 3, Multi-Center, Open-Label, Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of Two 6-Month Leuprolide Formulations, in Subjects With Prostatic Adenocarcinoma
L-CP07-177 AbbVie_IU_icons_outlined_v3 Central Precocious Puberty Phase 3 A 36 Month, Multi-Center, Open-Label Extension Study to Evaluate the Safety of Leuprolide Acetate 11.25 mg and 30 mg Formulations in Children with Central Precocious Puberty
P12-763 AbbVie_IU_icons_outlined_v3 Exploratory PMOS Prospective, Multi-Center, Observational Program to Assess Routine Use of Intermittent Adjuvant Deprivation Therapy With Lucrin Depot in Patients With Advanced Prostate Cancer in the Russian Federation
L-CP07-167 AbbVie_IU_icons_outlined_v3 Central Precocious Puberty Phase 3 A Phase 3, Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy and Safety of Leuprolide Acetate 11.25 and 30 mg Formulations in Children With Central Precocious Puberty
M90-516 AbbVie_IU_icons_outlined_v3 Central Precocious Puberty Phase 3 Study of Lupron Depot In The Treatment of Central Precocious Puberty
L-BT04-093 AbbVie_IU_icons_outlined_v3 Other Phase 2 Leuprolide Acetate to Enhance Immune Function Post-Autologous Stem Cell Transplantation
P12-811 AbbVie_IU_icons_outlined_v3 Prostate Cancer PMOS Canadian Real-Life Evaluation of the Effectiveness of Lupron in the Management of Prostate Cancer (CRONOS)